文献速递流行病学与生物统计临床试验与 GCP

发热成人退热治疗:系统评价与荟萃分析及试验序贯分析

Fever therapy in febrile adults: systematic review with meta-analyses and trial sequential analyses.
PubMed 文献 · BMJ · 2022-07-12

该系统评价纳入42项随机临床试验共5140例发热成人,评估退热治疗与无退热治疗的效果。荟萃分析和试验序贯分析显示,退热治疗似乎不影响死亡风险(RR 1.04,95%CI 0.90-1.19)和严重不良事件风险(RR 1.02,95%CI 0.89-1.17),非严重不良事件风险既不能确认也不能排除降低(RR 0.92,95%CI 0.67-1.25)。

要点

  • 退热治疗似乎不影响发热成人的死亡风险和严重不良事件风险。
  • 非严重不良事件风险既不能确认也不能排除降低(RR 0.92,95%CI 0.67-1.25)。
  • 所有纳入试验均被评估为高偏倚风险,证据确定性从高到极低不等。

核心结论

  • 退热治疗似乎不影响死亡风险和严重不良事件风险。

研究设计与样本

  • 系统评价与荟萃分析及试验序贯分析,纳入42项随机临床试验共5140例发热成人。
  • 检索CENTRAL、BIOSIS、CINAHL、MEDLINE、Embase、LILACS、Scopus和Web of Science Core Collection,从建库至2021年7月2日。
  • 纳入标准为任何原因发热的成人随机临床试验,试验组为任何退热治疗,对照组为无退热治疗(可含安慰剂/假处理)。
  • 23项试验评估11种不同退热药物,11项试验评估物理降温,8项试验评估退热药物联合物理降温。
  • 3007例为危重症患者,1892例为非危重症患者,3277例为感染性发热,1139例为非感染性发热。

主要发现

  • 退热治疗降低死亡风险的假设可被拒绝(RR 1.04,95%CI 0.90-1.19;I²=0%;P=0.62;16项试验;高确定性证据)。
  • 退热治疗降低严重不良事件风险的假设可被拒绝(RR 1.02,95%CI 0.89-1.17;I²=0%;P=0.78;16项试验;高确定性证据)。
  • 一项评估生活质量的试验显示退热治疗与对照组无差异。
  • 退热治疗降低非严重不良事件风险的假设既不能确认也不能拒绝(RR 0.92,95%CI 0.67-1.25;I²=66.5%;P=0.58;4项试验;极低确定性证据)。
  • 所有试验均被评估为高偏倚风险。

关键数值与推荐

  • 主要结局为全因死亡和严重不良事件,次要结局为生活质量和非严重不良事件。
  • 证据确定性采用GRADE方法评估。
  • 系统评价注册号:PROSPERO CRD42019134006。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有试验均被评估为高偏倚风险。
  • 非严重不良事件分析异质性I²=66.5%,证据确定性为极低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the effects of fever therapy compared with no fever therapy in a wide population of febrile adults. DESIGN: Systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. DATA SOURCES: CENTRAL, BIOSIS, CINAHL, MEDLINE, Embase, LILACS, Scopus, and Web of Science Core Collection, searched from their inception to 2 July 2021. ELIGIBILITY CRITERIA: Randomised clinical trials in adults diagnosed as having fever of any origin. Included experimental interventions were any fever therapy, and the control intervention had to be no fever therapy (with or without placebo/sham). DATA EXTRACTION AND SYNTHESIS: Two authors independently selected studies, extracted data, and assessed the risk of bias. Primary outcomes were all cause mortality and serious adverse events. Secondary outcomes were quality of life and non-serious adverse events. Aggregate data were synthesised with meta-analyses, subgroup analyses, and trial sequential analyses, and the evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. RESULTS: Forty two trials assessing 5140 participants were included. Twenty three trials assessed 11 different antipyretic drugs, 11 trials assessed physical cooling, and eight trials assessed a combination of antipyretic drugs and physical cooling. Of the participants, 3007 were critically ill, 1892 were non-critically ill, 3277 had infectious fever, and 1139 had non-infectious fever. All trials were assessed as being at high risk of bias. Meta-analysis and trial sequential analysis showed that the hypothesis that fever therapy reduces the risk of death (risk ratio 1.04, 95% confidence interval 0.90 to 1.19; I2=0%; P=0.62; 16 trials; high certainty evidence) and the risk of serious adverse events (risk ratio 1.02, 0.89 to 1.17; I2=0%; P=0.78; 16 trials; high certainty evidence) could be rejected. One trial assessing quality of life was included, showing no difference between fever therapy and control. Meta-analysis and trial sequential analysis showed that the hypothesis that fever therapy reduces the risk of non-serious adverse events could be neither confirmed nor rejected (risk ratio 0.92, 0.67 to 1.25; I2=66.5%; P=0.58; four trials; very low certainty evidence). CONCLUSIONS: Fever therapy does not seem to affect the risk of death and serious adverse events. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42019134006.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Holgersson J, Ceric A, Sethi N, et al. Fever therapy in febrile adults: systematic review with meta-analyses and trial sequential analyses. BMJ. 2022. PMID: 35820685. doi:10.1136/bmj-2021-069620

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。